



Bevacizumab (Avastin®)

Revision: 3

Policy Number: M-0001

Last Update: 6/4/2014

Payment will not be made for any use of these drugs outside of the criteria without prior authorization. The member may not be billed unless the member explicitly agrees in writing to be responsible for the charges in accordance with the contract/provider manual. Prior authorization will only be given if the provider demonstrates the intended use meets Medicare coverage guidelines.

When appropriate compendia references the use of one of the chemotherapeutic agents listed in this Article as part of a 'combination therapy', the drug is only approved for use in such 'combinations', and the documentation should reflect, and be specific about, the use of the additional 'combination therapy' drugs.

Coverage Guidelines:

FDA:

1. Metastatic colorectal cancer
2. Non-squamous non-small cell lung cancer
3. Glioblastoma
4. Metastatic renal cell carcinoma

Off Label:

1. Primary central nervous system cancers: anaplastic astrocytoma; anaplastic oligodendroglioma; mixed anaplastic oligoastrocytomas
2. Kidney cancer - clear cell, initial therapy
3. Ovarian cancer – epithelial ovarian cancer
4. Metastatic breast cancer (HER2 negative disease)

Coding Information:

HCPCS Code(s)

| | |
|-------|-------------------------------|
| J9035 | INJECTION, BEVACIZUMAB, 10 MG |
|-------|-------------------------------|



ICD-9 Code(s)

| | |
|------------------|---|
| 153.0 - 153.9 | MALIGNANT NEOPLASM OF HEPATIC FLEXURE - MALIGNANT NEOPLASM OF COLON UNSPECIFIED SITE |
| 154.0 | PROLIFERATIVE DIABETIC RETINOPATHY |
| 154.1 | MALIGNANT NEOPLASM OF RECTUM |
| 154.2 | MALIGNANT NEOPLASM OF ANAL CANAL |
| 154.3 | MALIGNANT NEOPLASM OF ANUS UNSPECIFIED SITE |
| 154.8 | MALIGNANT NEOPLASM OF OTHER SITES OF RECTUM RECTOSIGMOID JUNCTION AND ANUS |
| 157.0- 157.9 | MALIGNANT NEOPLASM OF HEAD OF PANCREAS - MALIGNANT NEOPLASM OF PANCREAS PART UNSPECIFIED |
| 162.0 - 162.9 | MALIGNANT NEOPLASM OF TRACHEA - MALIGNANT NEOPLASM OF BRONCHUS AND LUNG UNSPECIFIED |
| 174.0 - 174.9 | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF FEMALE BREAST - MALIGNANT NEOPLASM OF BREAST (FEMALE) UNSPECIFIED SITE |
| 175.0 | MALIGNANT NEOPLASM OF NIPPLE AND AREOLA OF MALE BREAST |
| 175.9 | MALIGNANT NEOPLASM OF OTHER AND UNSPECIFIED SITES OF MALE BREAST |
| 180.0 | MALIGNANT NEOPLASM OF ENDOCERVIX |
| 180.1 | MALIGNANT NEOPLASM OF EXOCERVIX |
| 180.8 | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF CERVIX |
| 180.9 | MALIGNANT NEOPLASM OF CERVIX UTERI UNSPECIFIED SITE |
| 183.0 | MALIGNANT NEOPLASM OF OVARY |
| 183.2 - 183.5 | MALIGNANT NEOPLASM OF FALLOPIAN TUBE - MALIGNANT NEOPLASM OF ROUND LIGAMENT OF UTERUS |
| 183.8 | MALIGNANT NEOPLASM OF OTHER SPECIFIED SITES OF UTERINE ADNEXA |
| 183.9 | MALIGNANT NEOPLASM OF UTERINE ADNEXA UNSPECIFIED SITE |
| 189.0 | MALIGNANT NEOPLASM OF KIDNEY EXCEPT PELVIS |
| 189.1 | MALIGNANT NEOPLASM OF RENAL PELVIS |
| 191.0 - 191.9 | MALIGNANT NEOPLASM OF CEREBRUM EXCEPT LOBES AND VENTRICLES - MALIGNANT NEOPLASM OF BRAIN UNSPECIFIED SITE |
| V10.00 | PERSONAL HISTORY OF MALIGNANT NEOPLASM OF UNSPECIFIED SITE IN GASTROINTESTINAL TRACT |
| V10.05 | PERSONAL HISTORY OF MALIGNANT NEOPLASM OF LARGE INTESTINE |
| V10.06 | PERSONAL HISTORY OF MALIGNANT NEOPLASM OF RECTUM RECTOSIGMOID JUNCTION AND ANUS |

This policy has been developed for informational purposes only and constitutes neither offers of coverage nor operates as a substitute for professional healthcare advice. This document contains confidential and proprietary information of VIVA Health which may not be reproduced, distributed or printed without prior permission from VIVA Health. In addition, it contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with VIVA Health. VIVA Health makes no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability of the information contained herein. VIVA Health assumes no responsibility for errors or omissions contained herein or any subsequent reliance upon said information.



| | |
|-------|--|
| V10.3 | PERSONAL HISTORY OF MALIGNANT NEOPLASM OF BREAST |
|-------|--|

Background:

Bevacizumab is a recombinant human monoclonal IgG1 antibody that reduces angiogenesis in neoplastic and other cells.

Definitions:

HCPCS Code—Healthcare Common Procedure Coding System - A system of letter and number codes assigned to procedures, medications, supplies and equipment used for pricing and billing.

ICD-9 Code—International Classification of Disease, 9th edition. A standardized classification of disease, injuries, and causes of death, by etiology and anatomic localization and codified into a 6-digit number, which allows clinicians, statisticians, politicians, health planners and others to speak a common language, both US and internationally.

FDA Black Box Warning:

WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE.

Gastrointestinal Perforations

The incidence of gastrointestinal perforation, some fatal, in Avastin-treated patients ranges from 0.3 to 2.4%. Discontinue Avastin in patients with gastrointestinal perforation.

Surgery and Wound Healing Complications

The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients. Discontinue Avastin in patients with wound dehiscence. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence has not been determined. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed.

Hemorrhage

Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, central nervous system (CNS) hemorrhage, epistaxis, and vaginal bleeding occurred up to five-fold more frequently in patients receiving Avastin. Do not administer Avastin to patients with serious hemorrhage or recent hemoptysis.



References:

1. Avastin [package insert]. South San Francisco, CA: Genentech, Inc.; May 2012. Available at: <http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf>. Accessed May 16, 2012.
2. The NCCN Drugs & Biologics Compendium™ © 2010 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed May 16, 2012.
3. Local Coverage Determination (LCD) for Drugs and Biologicals: Bevacizumab (AVASTIN®) (L29992). Available at: <http://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=29992&ContrlId=214&ver=39&ContrVer=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=Alabama&KeyWord=bevacizumab&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAABAAAA&>. Accessed May 16, 2012.
4. Local Coverage Article for Drugs and Biologicals – Chemotherapeutic Agents (A48896) (R4). Available at: http://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=48896&ver=92&ContrlId=213&ContrVer=1&CtrctrSelected=213*1&Date=01%2f01%2f2014&DocId=A48896&bc=hAAAAAgAAAAAA%3d%3d&. Accessed June 4, 2014.
5. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed August 1, 2013.
6. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. *Gynecol Oncol.* 2010 Feb;116(2):181-6. Accessed August 1, 2013.

Document History:

Date Written: 5/16/12

Effective Date: 4/01/2013

Revision 1: 3/19/2013

Revision 2: 8/2/2013

Revision 3: 6/4/2014

Internal Review: 6/9/2014

External Review: 6/17/2014

For the Archived Policy, please go

to <http://www.vivaprovider.com/Resources/CoveragePolicies.aspx> and click on the Archived Policies Link.